Activity

The aim of this study was to explore the suitability of a Christian 12-step program based on a biblical perspective for smartphone-addicted adolescents. The study found that “repentance” and “realizing ones’ calling” were the main similarities between the 12-step program’s core principles and biblical themes. Based on a biblical analysis the 12 step program however features some limitations, including an ambiguous definition of the “great power”, a superficial understanding of sin, and a need to consider adolescents’ characteristics. This study suggests the following strategies (1) diagnosis of adolescents’ image of God and transformation of this image into a biblical image of God, (2) intervention regarding sin through a holistic perspective, (3) adolescents’ recognition of their own calling, and (4) an adult counselor working to trigger social learning in 12 steps. Finally, for application within Christian counselling, the study suggests a cognitive therapeutic approach based on a biblical image of God and a systematic evaluative process of sin in addicted adolescents.Millions of Americans experience sadness, fatigue, and sleeping difficulty. These symptoms are consistent with a diagnosis of depression, which the American Psychiatric Association (APA) categorizes as a serious medical illness. Treatments include pharmacotherapy and/or counseling, with varying outcomes. selleck chemicals Anecdotally, positive outcomes are seen in adults with depressive symptoms seeking Biblical counseling (BC) that uses the Judeo-Christian Bible as its foundation; so, this project explored such a program. The project included a retrospective chart review and a pilot study introducing the use of the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) to identify and track depressive symptoms. Findings support further investigation into BC as a viable option.Chronic inflammatory diseases (CIDs) have complex pathologies that result from aberrant and persistent immune responses. However, the precise triggers and mechanisms remain elusive. An important aspect of CID research focuses on epigenetics modifications, which regulate gene expression and provide a dynamic transcriptional response to inflammation. In recent years, mounting evidence has demonstrated an association between epigenomic and transcriptomic dysregulation and the phenotypes of CIDs. In particular, epigenetic changes at cis-regulatory elements have provided new insights for immune cell-specific alterations that contribute to disease etiology. Furthermore, the advancements in single-cell genomics provide novel solutions to cell type heterogeneity, which has long posed challenges for CID diagnosis and treatment. In this review, we discuss the current state of epigenomics research of CID and the insights derived from single-cell transcriptomic and epigenomic studies.Taiping chicken is indigenous chickens (Gallus gallus domesticus), which was one of China’s excellent poultry species, is an excellent chicken in Gansu Province. As the problems caused by the overuse of antibiotics become more and more severe, people begin to look for ways to replace them. Among them, probiotics and fructo-oligosaccharides are the research hotspot to replace antibiotics. Probiotics and fructo-oligosaccharides can promote the absorption of nutrients, improve the ability to resist and prevent diseases, and improve the intestinal tissue morphology. In this study, we used RNA-Seq analysis to study the gene expression in ileum tissue after Taiping chicken was given probiotics and fructo-oligosaccharides. In total, 67 genes were differentially expressed in the ileum. Ten of the differently expressed genes were further validated by RT-qPCR. In addition, these differentially expressed genes were mainly enriched to tyrosine metabolism, AGE-RAGE signaling pathway in diabetic complications, phenylalanine metabolism, and pyrimidine metabolism. The results which this study provides contribute to our understanding application of probiotics and fructo-oligosaccharides in indigenous chickens production and provide a theoretical basis for the genetic development of indigenous chickens.

The potential of metamizole to cause drug-induced liver injury (DILI) has received increasing attention. We investigated the distinguishing features of a case series comprising 32 patients with suspected metamizole-induced DILI.

For the current analysis, 32 of 238 patients with DILI included in our prospective study on drugs potentially causing DILI were included. Diagnosis of DILI was based on expert opinion and RUCAM (Roussel Uclaf Causality Assessment Method) score and supported by an in vitro test using monocyte-derived hepatocyte-like cells.

Suspected metamizole-DILI was characterised by a female predominance, hepatocellular pattern of injury, high proportion of antinuclear antibody positivity, and predominance of eosinophilic cell infiltration and necrosis in the histopathological analysis. With 22%, a high proportion of these metamizole-associated liver injury cases developed acute liver failure, which was characterised by a longer latency of metamizole use and more pronounced liver biochemistry abnormalities at onset and peak levels. Furthermore, jaundice was a common finding in the metamizole-associated liver injury cases with 66% presenting with peak bilirubin levels of 3mg/dL or higher, which was associated with a worse outcome and a higher frequency of acute liver failure.

Our analysis of a well-characterised DILI cohort further supports the potential of metamizole causing DILI and provides important features for the establishment of a signature pattern of liver injury observed in patients treated with metamizole.

ClinicalTrials.gov NCT02353455.

ClinicalTrials.gov NCT02353455.

Previously, we conducted the 5-year open-label, randomized controlled trial (RCT) of leuprorelin adjuvant therapy in post-operative premenopausal patients with endocrine-responsive breast cancer, which was a pilot study to investigate the optimal duration of leuprorelin treatment. Since, however, long-term outcomes became required for the adjuvant endocrine therapy, we performed this follow-up observation study.

Follow-up observation study was performed up to 10th year after randomization, continuing RCT to evaluate the efficacy and safety of leuprorelin every 3months for ≥ 3 versus 2years, with daily tamoxifen for 5years. Primary endpoints were disease-free survival (DFS) and 2-year landmark DFS.

Eligible patients (N = 222) were randomly assigned to receive leuprorelin for either 2years (N = 112) or ≥ 3years (N = 110) with tamoxifen. Leuprorelin treatment for ≥ 3years versus 2years provided no significant difference in DFS (HR 0.944, 95% CI 0.486-1.8392) or 2-year landmark DFS (N = 99 and 102 in 2-year and ≥ 3-year groups, HR 0.